Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Are poison pills really that bitter?

Are poison pills really that bitter?

FromEquity


Are poison pills really that bitter?

FromEquity

ratings:
Length:
9 minutes
Released:
Apr 18, 2022
Format:
Podcast episode

Description

Every Monday, Grace and Alex scour the news and record notes on what’s going on to kick off the week.We are sitting on the precipice of a very busy few weeks, so let's get right to work!Stocks are mixed around the world to start the day, cryptos are off a little more but nothing too scary.Didi will vote on leaving the US public markets this May, and has promised to not list anywhere else in the interim. This saga is nearly behind us, but what a mess it will leave in its wake.The Beanstalk exploit was bad news this weekend, but my hunch is that so long as votes are tied to economic might, many neat ideas in crypto-land will remain open to exploit.Zambian fintech startup Union54 raised a $12 million Seed extension, led by Tiger, that caught our eye. And over in India, food-delivery rivals Swiggy and Zomato are both backing UrbanPiper.Finally, it seems that some private-market investors are not stoked about poison pills, a defensive setup by public companies to prevent a hostile takeover. Which makes me laugh, as dual-class shares that many VCs either back, or at least help fund amongst hot startups are similar in that they are also designed to prevent changes of control.To close, we have a live show this week! Yes, a live show. So come hang out with us on Thursday as we record our Friday episode!
Released:
Apr 18, 2022
Format:
Podcast episode

Titles in the series (100)

Equity is TechCrunch’s venture capital podcast. In each episode, we bring you the numbers behind the headlines in Venture Captial. TechCrunch reporter Alex Wilhelm teams up with Danny Crichton and Natasha Mascarenhas to give a window into startup land.